Latest period
$1.37B
YoY change
+24.6%
5Y CAGR
+8.8%
Peak year (2025)
$1.21B
Cumulative CapEx
$10.79B
CapEx history chart for AbbVie (ABBV) from 2009 to 2025
Latest: $1.21B
CapEx growth chart for AbbVie (ABBV) from 2009 to 2025
Latest: +24.6%
CapEx history table for AbbVie (ABBV) from 2009 to 2025
| 2025 | $1.21B | +24.6% | +$240.00M | ||
| 2024 | $974.00M | +25.4% | +$197.00M | ||
| 2023 | $777.00M | +11.8% | +$82.00M | ||
| 2022 | $695.00M | -11.7% | −$92.00M | ||
| 2021 | $787.00M | -1.4% | −$11.00M | ||
| 2020 | $798.00M | +44.6% | +$246.00M | ||
| 2019 | $552.00M | -13.5% | −$86.00M | ||
| 2018 | $638.00M | +20.6% | +$109.00M | ||
| 2017 | $529.00M | +10.4% | +$50.00M | ||
| 2016 | $479.00M | -10.0% | −$53.00M | ||
| 2015 | $532.00M | -13.1% | −$80.00M | ||
| 2014 | $612.00M | +24.6% | +$121.00M | ||
| 2013 | $491.00M | +47.4% | +$158.00M | ||
| 2012 | $333.00M | -6.3% | −$22.52M | ||
| 2011 | $355.51M | -20.6% | −$92.48M | ||
| 2010 | $448.00M | +43.3% | +$135.44M | ||
| 2009 | $312.56M | — | — |
- 2025$1.21B+24.6%
- 2024$974.00M+25.4%
- 2023$777.00M+11.8%
- 2022$695.00M-11.7%
- 2021$787.00M-1.4%
- 2020$798.00M+44.6%
- 2019$552.00M-13.5%
- 2018$638.00M+20.6%
- 2017$529.00M+10.4%
- 2016$479.00M-10.0%
- 2015$532.00M-13.1%
- 2014$612.00M+24.6%
- 2013$491.00M+47.4%
- 2012$333.00M-6.3%
- 2011$355.51M-20.6%
- 2010$448.00M+43.3%
- 2009$312.56M—
CapEx values are taken from AbbVie's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current CapEx (TTM) is $1.37B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AbbVie (ABBV) most recent annual CapEx stands at $1.21B (2025) – grew 24.6% year-over-year.
Through 2020–2025 (5 years), AbbVie CapEx delivered a +8.8% annualised rate; sustaining 3 straight years of year-over-year growth.
2025 marks the peak CapEx at $1.21B, with the historical low of $312.56M recorded in 2009.
AbbVie Capital Expenditures by Year
AbbVie Capital Expenditures 2025: $1.21B
In 2025, AbbVie reported CapEx of $1.21B, grew 24.6% from 2024. This figure represents the highest annual value in the available history.
AbbVie Capital Expenditures 2024: $974.00M
AbbVie CapEx in 2024 was $974.00M, grew 25.4% from 2023.
AbbVie Capital Expenditures 2023: $777.00M
2023's CapEx for AbbVie came in at $777.00M, grew 11.8% from 2022.
AbbVie Capital Expenditures 2022: $695.00M
AbbVie posted CapEx of $695.00M in 2022, declined 11.7% below 2021.
AbbVie Capital Expenditures 2021: $787.00M
AbbVie CapEx in 2021 was $787.00M.
See more financial history for AbbVie (ABBV).
Sector peers by CapEx
Healthcare peers of AbbVie (ABBV), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.52B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation